Canopy Growth Braces for August Earnings Amid German Policy Shift and Insider Selling

Canopy Growth shares have lost over 50% from their 52-week high as insider selling and Germany's cannabis flower reimbursement ban weigh on the cannabis producer ahead of its August 7 earnings report.

The clock is ticking toward Canopy Growth’s next quarterly report on August 7, 2026, and the company enters the release with a stock that has lost more than half its value since touching a 52-week high of €2.00 in December. At Friday’s close of €0.8078, the equity sits just 7.71% above its March 2026 nadir of €0.75, and year-to-date the decline stands at 22.48%. The market now capitalizes the cannabis producer at roughly €373 million — a far cry from the valuation of the consumer-goods giants it is occasionally measured against.

Behind those share-price mechanics, a more fundamental tension is playing out. On one side, Canada’s export machine is roaring: the country shipped more than 275 tonnes of medical cannabis in 2025, a 143% surge year-over-year, and German imports of medical cannabis jumped 298% over the same period. On the other, Germany — previously one of Europe’s most promising medical-cannabis markets — recently decided to exclude cannabis flower from reimbursement by statutory health insurers, a move that could blunt demand just as Canadian producers look abroad for growth.

Insider activity adds another layer of caution. Over the past 90 days, company insiders have sold a total of 224,958 shares. Among the most notable transactions: CEO Luc Mongeau disposed of 135,231 shares at US$0.97 each, while director Christelle Gedeon sold 58,994 shares at the same price. Institutional ownership currently sits at just 3.33%, underscoring the limited big-money conviction in the stock.

The financial figures from the most recent completed quarter, the fourth quarter of fiscal 2026, highlight the uphill climb to profitability. Revenue came in at US$51.95 million (roughly C$71.2 million), while the adjusted loss per share was US$0.29. Those results — more current than the fiscal 2025 numbers that showed a net loss of C$598.12 million on revenue of C$269 million — reflect management’s ongoing effort to reshape the cost base in an increasingly competitive landscape.

Against that backdrop, analyst opinion remains split but leans cautious. Of the six analysts covering the name, two rate it a “buy,” three recommend “hold,” and one says “sell.” The consensus effectively calls for patience until clearer signs of a sustainable recovery emerge. For investors, the August 7 print will be the next critical data point — one that will either justify the current skittishness or provide the operational proof needed to rebuild confidence.